NASDAQ:OBIO Orchestra BioMed (OBIO) Stock Price, News & Analysis $3.90 -0.09 (-2.26%) Closing price 04:00 PM EasternExtended Trading$3.89 -0.01 (-0.26%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Orchestra BioMed Stock (NASDAQ:OBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Orchestra BioMed alerts:Sign Up Key Stats Today's Range$3.81▼$4.1450-Day Range$3.72▼$4.5852-Week Range$2.20▼$5.42Volume138,772 shsAverage Volume247,281 shsMarket Capitalization$233.53 millionP/E RatioN/ADividend YieldN/APrice Target$13.60Consensus RatingModerate Buy Company Overview Orchestra BioMed, Inc. (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis. Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs. The company’s development strategy emphasizes streamlined trial design and biomarker-driven patient selection, with the goal of demonstrating safety and efficacy in well-defined patient populations. In parallel, Orchestra evaluates combination approaches and seeks strategic collaborations to broaden the therapeutic reach of its candidates across multiple disease indications. Headquartered in the United States, Orchestra BioMed is led by a management team with extensive experience in drug discovery, clinical development and regulatory affairs. The company operates under a governance framework committed to scientific rigor and transparent communication with investors and collaborators. Orchestra BioMed continues to build its capabilities through targeted investments in research infrastructure and external partnerships, positioning itself to address significant challenges in fibrotic, inflammatory and oncologic disease management.AI Generated. May Contain Errors. Read More Orchestra BioMed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreOBIO MarketRank™: Orchestra BioMed scored higher than 92% of companies evaluated by MarketBeat, and ranked 35th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingOrchestra BioMed has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialOrchestra BioMed has a consensus price target of $13.60, representing about 248.7% upside from its current price of $3.90.Amount of Analyst CoverageOrchestra BioMed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Orchestra BioMed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Orchestra BioMed are expected to grow in the coming year, from ($1.47) to ($1.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Orchestra BioMed is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orchestra BioMed is -4.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOrchestra BioMed has a P/B Ratio of 4.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Orchestra BioMed's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.52% of the float of Orchestra BioMed has been sold short.Short Interest Ratio / Days to CoverOrchestra BioMed has a short interest ratio ("days to cover") of 3.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Orchestra BioMed has recently decreased by 13.40%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrchestra BioMed does not currently pay a dividend.Dividend GrowthOrchestra BioMed does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.16 News SentimentOrchestra BioMed has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Orchestra BioMed this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Orchestra BioMed to their MarketBeat watchlist in the last 30 days. Company Ownership4.5 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Orchestra BioMed in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $142,931.00 in company stock, which represents 0.0612% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Orchestra BioMed insiders have bought 246.22% more of their company's stock than they have sold. Specifically, they have bought $200,981.00 in company stock and sold $58,050.00 in company stock.Percentage Held by Insiders7.50% of the stock of Orchestra BioMed is held by insiders.Percentage Held by Institutions53.20% of the stock of Orchestra BioMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Orchestra BioMed's insider trading history. Receive OBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orchestra BioMed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OBIO Stock News HeadlinesDavid Hochman Buys 5,000 Shares of Orchestra BioMed (NASDAQ:OBIO) StockJune 3 at 6:44 AM | insidertrades.comOrchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Recommendation of "Moderate Buy" by AnalystsJune 3 at 3:27 AM | americanbankingnews.comTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.June 5 at 1:00 AM | Reagan Gold Group (Ad)Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 2 at 4:05 PM | globenewswire.comInsider Buying: Orchestra BioMed (NASDAQ:OBIO) Insider Purchases 5,000 Shares of StockMay 20, 2026 | insidertrades.comOrchestra BioMed to Participate in the Jefferies Global Healthcare ConferenceMay 19, 2026 | globenewswire.comInsider Buying: Orchestra BioMed (NASDAQ:OBIO) Director Purchases 20,000 Shares of StockMay 19, 2026 | insidertrades.comOrchestra BioMed Holdings (OBIO) Receives a Buy from H.C. WainwrightMay 16, 2026 | theglobeandmail.comSee More Headlines OBIO Stock Analysis - Frequently Asked Questions How have OBIO shares performed this year? Orchestra BioMed's stock was trading at $4.15 at the beginning of the year. Since then, OBIO stock has decreased by 6.0% and is now trading at $3.90. How were Orchestra BioMed's earnings last quarter? Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) posted its quarterly earnings data on Tuesday, May, 12th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.07. The business earned $0.11 million during the quarter, compared to analyst estimates of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative trailing twelve-month return on equity of 157.46%. When did Orchestra BioMed IPO? Orchestra BioMed (OBIO) raised $139 million in an initial public offering (IPO) on Tuesday, August 4th 2020. The company issued 13,913,044 shares at a price of $10.00 per share. Who are Orchestra BioMed's major shareholders? Orchestra BioMed's top institutional investors include Perceptive Advisors LLC (8.41%), Affinity Asset Advisors LLC (0.67%), Knott David M Jr (0.42%) and Simplify Asset Management Inc. (0.37%). Insiders that own company stock include Darren Sherman, David P Hochman, William Reed Little, Jason Aryeh and Eric S Fain. View institutional ownership trends. How do I buy shares of Orchestra BioMed? Shares of OBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Orchestra BioMed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orchestra BioMed investors own include Tesla (TSLA), JPMorgan Chase & Co. (JPM), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings5/12/2026Today6/05/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 OBIO's financial health is in the Green zone, according to TradeSmith. OBIO has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:OBIO CIK1814114 Weborchestrabiomed.com Phone646-597-6980FaxN/AEmployees4Year Founded2018Price Target and Rating Average Price Target for Orchestra BioMed$13.60 High Price Target$20.00 Low Price Target$10.00 Potential Upside/Downside+248.7%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.97) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$52.70 million Net Margins-166.96% Pretax Margin-166.96% Return on Equity-157.46% Return on Assets-60.18% Debt Debt-to-Equity Ratio0.35 Current Ratio7.03 Quick Ratio7.01 Sales & Book Value Annual Sales$33.48 million Price / Sales6.98 Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book4.11Miscellaneous Outstanding Shares59,880,000Free Float55,390,000Market Cap$233.53 million OptionableNot Optionable Beta0.50 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:OBIO) was last updated on 6/5/2026 by MarketBeat.com Staff. From Our Partners$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orchestra BioMed Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orchestra BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
